Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
October 24, 2018 08:00 ET
|
Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine) Extended-Release...
Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)
October 23, 2018 08:00 ET
|
Neos Therapeutics, Inc.
Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options Development Strategy Leverages Neos’ Modified-Release...